{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Head+and+Neck+Squamous+Cell+Carcinoma+%28HNSCC%29&page=46",
    "query": {
      "condition": "Head and Neck Squamous Cell Carcinoma (HNSCC)",
      "page": 46
    },
    "page_size": 10
  },
  "pagination": {
    "page": 46,
    "page_size": 10,
    "total_count": 1194,
    "total_pages": 120,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Head+and+Neck+Squamous+Cell+Carcinoma+%28HNSCC%29&page=47&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Head+and+Neck+Squamous+Cell+Carcinoma+%28HNSCC%29&page=45&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-16T10:48:19.996Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02499120",
      "title": "Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Squamous Cell Carcinoma of the Head and Neck (SCCHN)"
      ],
      "interventions": [
        {
          "name": "palbociclib",
          "type": "DRUG"
        },
        {
          "name": "Cetuximab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 125,
      "start_date": "2015-09-10",
      "completion_date": "2022-09-07",
      "has_results": true,
      "last_update_posted_date": "2023-09-08",
      "last_synced_at": "2026-10-16T10:48:19.996Z",
      "location_count": 14,
      "location_summary": "La Jolla, California • San Diego, California • Louisville, Kentucky + 7 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02499120"
    },
    {
      "nct_id": "NCT00049283",
      "title": "Erlotinib, Docetaxel, and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma",
        "Stage III Squamous Cell Carcinoma of the Hypopharynx",
        "Stage III Squamous Cell Carcinoma of the Larynx",
        "Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Stage III Squamous Cell Carcinoma of the Nasopharynx",
        "Stage III Squamous Cell Carcinoma of the Oropharynx",
        "Stage III Verrucous Carcinoma of the Larynx",
        "Stage III Verrucous Carcinoma of the Oral Cavity",
        "Stage IV Squamous Cell Carcinoma of the Hypopharynx",
        "Stage IV Squamous Cell Carcinoma of the Nasopharynx",
        "Stage IVA Squamous Cell Carcinoma of the Larynx",
        "Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Stage IVA Squamous Cell Carcinoma of the Oropharynx",
        "Stage IVA Verrucous Carcinoma of the Larynx",
        "Stage IVA Verrucous Carcinoma of the Oral Cavity",
        "Stage IVB Squamous Cell Carcinoma of the Larynx",
        "Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Stage IVB Squamous Cell Carcinoma of the Oropharynx",
        "Stage IVB Verrucous Carcinoma of the Larynx",
        "Stage IVB Verrucous Carcinoma of the Oral Cavity",
        "Stage IVC Squamous Cell Carcinoma of the Larynx",
        "Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Stage IVC Squamous Cell Carcinoma of the Oropharynx",
        "Stage IVC Verrucous Carcinoma of the Larynx",
        "Stage IVC Verrucous Carcinoma of the Oral Cavity",
        "Tongue Cancer",
        "Untreated Metastatic Squamous Neck Cancer With Occult Primary"
      ],
      "interventions": [
        {
          "name": "erlotinib hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "docetaxel",
          "type": "DRUG"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        },
        {
          "name": "therapeutic conventional surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2002-09",
      "completion_date": "2008-02",
      "has_results": false,
      "last_update_posted_date": "2014-06-06",
      "last_synced_at": "2026-10-16T10:48:19.996Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00049283"
    },
    {
      "nct_id": "NCT04429542",
      "title": "Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Head and Neck Squamous Cell Carcinoma",
        "Squamous Cell Carcinoma of Anal Canal",
        "Colorectal Cancer",
        "Squamous Cell Carcinoma of the Lung",
        "EGFR Amplification",
        "Epithelial Ovarian Cancer",
        "Pancreas Cancer",
        "Cutaneous Squamous Cell Carcinoma",
        "Head and Neck Neoplasms",
        "Carcinoma, Squamous Cell",
        "Squamous Cell Carcinoma of Head and Neck"
      ],
      "interventions": [
        {
          "name": "BCA101",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bicara Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 473,
      "start_date": "2020-06-01",
      "completion_date": "2028-03-30",
      "has_results": false,
      "last_update_posted_date": "2026-10-06",
      "last_synced_at": "2026-10-16T10:48:19.996Z",
      "location_count": 15,
      "location_summary": "La Jolla, California • Los Angeles, California • Sacramento, California + 10 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04429542"
    },
    {
      "nct_id": "NCT06096038",
      "title": "Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Head and Neck Cancer",
        "Relapse",
        "Recurrent",
        "Refractory Cancer"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Cell Therapy",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "UNC Lineberger Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2024-04-05",
      "completion_date": "2028-08-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-16",
      "last_synced_at": "2026-10-16T10:48:19.996Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06096038"
    },
    {
      "nct_id": "NCT00006994",
      "title": "S9908: Glutamine in Treating Mucositis Caused by Radiation Therapy in Patients With Newly Diagnosed Cancer of the Mouth or Throat",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cancer-related Problem/Condition",
        "Head and Neck Cancer",
        "Pain"
      ],
      "interventions": [
        {
          "name": "glutamine",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        },
        {
          "name": "l-glutamine placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "RADIATION",
        "DRUG"
      ],
      "sponsor": "SWOG Cancer Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 23,
      "start_date": "2001-11",
      "completion_date": "2006-04",
      "has_results": false,
      "last_update_posted_date": "2015-11-18",
      "last_synced_at": "2026-10-16T10:48:19.996Z",
      "location_count": 106,
      "location_summary": "Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 68 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00006994"
    },
    {
      "nct_id": "NCT00098631",
      "title": "Lapatinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Squamous Neck Cancer With Occult Primary",
        "Recurrent Metastatic Squamous Neck Cancer With Occult Primary",
        "Recurrent Squamous Cell Carcinoma of the Hypopharynx",
        "Recurrent Squamous Cell Carcinoma of the Larynx",
        "Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Recurrent Squamous Cell Carcinoma of the Nasopharynx",
        "Recurrent Squamous Cell Carcinoma of the Oropharynx",
        "Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity",
        "Salivary Gland Squamous Cell Carcinoma",
        "Stage IV Squamous Cell Carcinoma of the Hypopharynx",
        "Stage IV Squamous Cell Carcinoma of the Larynx",
        "Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Stage IV Squamous Cell Carcinoma of the Nasopharynx",
        "Stage IV Squamous Cell Carcinoma of the Oropharynx",
        "Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity",
        "Untreated Metastatic Squamous Neck Cancer With Occult Primary"
      ],
      "interventions": [
        {
          "name": "lapatinib ditosylate",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 88,
      "start_date": "2004-10",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2014-01-07",
      "last_synced_at": "2026-10-16T10:48:19.996Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00098631"
    },
    {
      "nct_id": "NCT03085147",
      "title": "A Dye for the Detection of Cancer of the Tongue and Mouth",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Oral Squamous Cell Carcinoma (OSCC)"
      ],
      "interventions": [
        {
          "name": "Olaparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 23,
      "start_date": "2017-03-15",
      "completion_date": "2027-07",
      "has_results": false,
      "last_update_posted_date": "2026-08-04",
      "last_synced_at": "2026-10-16T10:48:19.996Z",
      "location_count": 7,
      "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more",
      "locations": [
        {
          "city": "Basking Ridge",
          "state": "New Jersey"
        },
        {
          "city": "Middletown",
          "state": "New Jersey"
        },
        {
          "city": "Montvale",
          "state": "New Jersey"
        },
        {
          "city": "Commack",
          "state": "New York"
        },
        {
          "city": "Harrison",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03085147"
    },
    {
      "nct_id": "NCT00443261",
      "title": "Azacitidine and Cisplatin for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Azacitidine",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Kansas Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2007-02",
      "completion_date": "2008-06",
      "has_results": true,
      "last_update_posted_date": "2017-02-27",
      "last_synced_at": "2026-10-16T10:48:19.996Z",
      "location_count": 1,
      "location_summary": "Kansas City, Missouri",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00443261"
    },
    {
      "nct_id": "NCT03085719",
      "title": "Targeting PD-1 Therapy Resistance With Focused High or High and Low Dose Radiation in SCCHN",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck Cancer"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Radiation",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2017-06-30",
      "completion_date": "2027-10-31",
      "has_results": true,
      "last_update_posted_date": "2026-06-15",
      "last_synced_at": "2026-10-16T10:48:19.996Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03085719"
    },
    {
      "nct_id": "NCT05544929",
      "title": "A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung",
        "Cutaneous Melanoma",
        "Carcinoma, Renal Cell",
        "Carcinoma, Ovarian Epithelial",
        "Nasopharyngeal Carcinoma",
        "Carcinoma, Thymic",
        "Anal Cancer",
        "Mesothelioma",
        "Esophagogastric Cancer",
        "High Microsatellite Instability Colorectal Carcinoma",
        "Squamous Cell Carcinoma of Head and Neck",
        "Triple Negative Breast Neoplasms"
      ],
      "interventions": [
        {
          "name": "KFA115",
          "type": "DRUG"
        },
        {
          "name": "pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 126,
      "start_date": "2022-10-26",
      "completion_date": "2027-09-01",
      "has_results": false,
      "last_update_posted_date": "2026-01-06",
      "last_synced_at": "2026-10-16T10:48:19.996Z",
      "location_count": 5,
      "location_summary": "Boston, Massachusetts • New York, New York • Pittsburgh, Pennsylvania + 1 more",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05544929"
    }
  ]
}